{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:10:25Z","timestamp":1777493425918,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008908","name":"Universit\u00e0 degli Studi di Messina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ejmech.2018.11.073","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T21:33:14Z","timestamp":1543613594000},"page":"443-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety"],"prefix":"10.1016","volume":"163","author":[{"given":"Maria Rosa","family":"Buemi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0841-9626","authenticated-orcid":false,"given":"Stefania","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona Maria","family":"Monti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Buonanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanbattista","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":false,"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0002-2253","authenticated-orcid":false,"given":"Rosaria","family":"Gitto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.11.073_bib1","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.11.073_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.11.073_bib3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/13543776.2016.1203904","article-title":"Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016)","volume":"26","author":"Lomelino","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2018.11.073_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/17460441.2017.1253677","article-title":"Advances in structure-based drug discovery of carbonic anhydrase inhibitors","volume":"12","author":"Supuran","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.11.073_bib5","series-title":"Carbonic Anhydrases as Biocatalysts: from Theory to Medical and Industrial Applications","author":"Supuran","year":"2015"},{"key":"10.1016\/j.ejmech.2018.11.073_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/14756366.2015.1122001","article-title":"How many carbonic anhydrase inhibition mechanisms exist?","volume":"31","author":"Supuran","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.gene.2017.04.027","article-title":"Carbonic anhydrase XII functions in health and disease","volume":"623","author":"Waheed","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2018.11.073_bib8","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/med.21497","article-title":"Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one","volume":"38","author":"Supuran","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2018.11.073_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14756366.2017.1405263","article-title":"Crystal structure of the human carbonic anhydrase II adduct with 1-(4-sulfamoylphenyl-ethyl)-2,4,6-triphenylpyridinium perchlorate, a membrane-impermeant, isoform selective inhibitor","volume":"33","author":"Alterio","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543776.2013.798648","article-title":"Anticancer carbonic anhydrase inhibitors: a patent review (2008 - 2013)","volume":"23","author":"Monti","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2018.11.073_bib11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/cmdc.201500596","article-title":"Vivo evaluation of selective carbonic anhydrase inhibitors as potential anticonvulsant agents","volume":"11","author":"Bruno","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.11.073_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1517\/14728214.2012.664132","article-title":"Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity","volume":"17","author":"Supuran","year":"2012","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejmech.2018.11.073_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/14728214.13.2.383","article-title":"Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity","volume":"13","author":"Supuran","year":"2008","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejmech.2018.11.073_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1747-0285.2009.00857.x","article-title":"Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates?","volume":"74","author":"De Simone","year":"2009","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2018.11.073_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-94-007-7359-2_14","article-title":"Carbonic anhydrases and brain pH in the control of neuronal excitability","volume":"75","author":"Ruusuvuori","year":"2014","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib16","doi-asserted-by":"crossref","first-page":"C1091","DOI":"10.1152\/ajpcell.00177.2009","article-title":"Bicarbonate homeostasis in excitable tissues: role of AE3 Cl-\/HCO3- exchanger and carbonic anhydrase XIV interaction","volume":"297","author":"Casey","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejmech.2018.11.073_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejmech.2015.07.049","article-title":"Carbonic anhydrase inhibitors: design, synthesis and structural characterization of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms","volume":"102","author":"Buemi","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejmech.2017.11.061","article-title":"Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases","volume":"143","author":"De Luca","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib19","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1021\/acs.jmedchem.7b00264","article-title":"Probing molecular interactions between human carbonic anhydrases (hCAs) and a novel class of benzenesulfonamides","volume":"60","author":"Bruno","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejmech.2013.10.071","article-title":"Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors","volume":"71","author":"De Luca","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib21","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/jm300112w","article-title":"Synthesis, structure-activity relationship studies, and X-ray crystallographic analysis of arylsulfonamides as potent carbonic anhydrase inhibitors","volume":"55","author":"Gitto","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib22","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1016\/j.bmc.2011.10.015","article-title":"Synthesis and biological profile of new 1,2,3,4-tetrahydroisoquinolines as selective carbonic anhydrase inhibitors","volume":"19","author":"Gitto","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib23","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1021\/jm2000213","article-title":"Structural basis for the interaction between carbonic anhydrase and 1,2,3,4-tetrahydroisoquinolin-2-ylsulfonamides","volume":"54","author":"Mader","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/cmdc.201000044","article-title":"Identification of potent and selective human carbonic anhydrase VII (hCA VII) inhibitors","volume":"5","author":"Gitto","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.11.073_bib25","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1021\/jm9014026","article-title":"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies","volume":"53","author":"Gitto","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib26","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1016\/j.bmc.2009.03.066","article-title":"Synthesis and evaluation of pharmacological profile of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides","volume":"17","author":"Gitto","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib27","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1016\/j.bmc.2011.10.015","article-title":"Synthesis and biological profile of new 1,2,3,4-tetrahydroisoquinolines as selective carbonic anhydrase inhibitors","volume":"19","author":"Gitto","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.neuropharm.2003.11.028","article-title":"Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy","volume":"46","author":"Russo","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2018.11.073_bib29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1517\/17460441.2013.795145","article-title":"Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors","volume":"8","author":"De Simone","year":"2013","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.11.073_bib30","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.bmcl.2006.12.113","article-title":"Carbonic anhydrase inhibitors. Inhibition of transmembrane isozymes XII (cancer-associated) and XIV with anions","volume":"17","author":"Innocenti","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.11.073_bib31","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1016\/j.bmcl.2005.06.055","article-title":"Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides","volume":"15","author":"Nishimori","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.11.073_bib32","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.1021\/jm050483n","article-title":"Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors","volume":"48","author":"Nishimori","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.11.073_bib33","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.bmcl.2010.07.051","article-title":"Crystal structure of the C183S\/C217S mutant of human CA VII in complex with acetazolamide","volume":"20","author":"Di Fiore","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.11.073_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061571","article-title":"The crystal structure of a hCA VII variant provides insights into the molecular determinants responsible for its catalytic behavior","volume":"19","author":"Buonanno","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2018.11.073_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejmech.2018.11.073_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/prot.340040406","article-title":"Refined structure of human carbonic anhydrase II at 2.0 A resolution","volume":"4","author":"Eriksson","year":"1988","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2018.11.073_bib37","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1107\/S0907444998003254","article-title":"Crystallography & NMR system: a new software suite for macromolecular structure determination","volume":"54","author":"Brunger","year":"1998","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2018.11.073_bib38","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/nprot.2007.406","article-title":"Version 1.2 of the crystallography and NMR system","volume":"2","author":"Brunger","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2018.11.073_bib39","doi-asserted-by":"crossref","first-page":"11636","DOI":"10.1039\/c1cc14575d","article-title":"Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of N-substituted benzenesulfonamides to human isoform II","volume":"47","author":"Di Fiore","year":"2011","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2018.11.073_bib40","doi-asserted-by":"crossref","first-page":"8838","DOI":"10.1039\/c2cc34275h","article-title":"Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors","volume":"48","author":"Di Fiore","year":"2012","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2018.11.073_bib41","doi-asserted-by":"crossref","first-page":"11519","DOI":"10.1039\/C5CC03711E","article-title":"Hydroxylamine-O-sulfonamide is a versatile lead compound for the development of carbonic anhydrase inhibitors","volume":"51","author":"Di Fiore","year":"2015","journal-title":"Chem. Commun."},{"issue":"Pt 2","key":"10.1016\/j.ejmech.2018.11.073_bib42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1107\/S0108767390010224","article-title":"Improved methods for building protein models in electron density maps and the location of errors in these models","volume":"47","author":"Jones","year":"1991","journal-title":"Acta Crystallogr. Section A, Found. Crystallogr."},{"key":"10.1016\/j.ejmech.2018.11.073_bib43","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1107\/S0907444904011679","article-title":"PRODRG: a tool for high-throughput crystallography of protein-ligand complexes","volume":"60","author":"Schuttelkopf","year":"2004","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418310353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418310353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:50:57Z","timestamp":1759326657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418310353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":43,"alternative-id":["S0223523418310353"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.073","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}